KR100547923B1 - 생체내내성이증가된제제 - Google Patents

생체내내성이증가된제제 Download PDF

Info

Publication number
KR100547923B1
KR100547923B1 KR1019980018269A KR19980018269A KR100547923B1 KR 100547923 B1 KR100547923 B1 KR 100547923B1 KR 1019980018269 A KR1019980018269 A KR 1019980018269A KR 19980018269 A KR19980018269 A KR 19980018269A KR 100547923 B1 KR100547923 B1 KR 100547923B1
Authority
KR
South Korea
Prior art keywords
formula
compound
active compound
acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019980018269A
Other languages
English (en)
Korean (ko)
Other versions
KR19980087239A (ko
Inventor
클라우스 보쓸레트
외르크 체흐
만프레드 게르켄
라이너 슈트라우프
마티아스 블룸리히
Original Assignee
훽스트 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훽스트 악티엔게젤샤프트 filed Critical 훽스트 악티엔게젤샤프트
Publication of KR19980087239A publication Critical patent/KR19980087239A/ko
Application granted granted Critical
Publication of KR100547923B1 publication Critical patent/KR100547923B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019980018269A 1997-05-15 1998-05-15 생체내내성이증가된제제 Expired - Fee Related KR100547923B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit
DE19720312.4 1997-05-15

Publications (2)

Publication Number Publication Date
KR19980087239A KR19980087239A (ko) 1998-12-05
KR100547923B1 true KR100547923B1 (ko) 2006-04-12

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980018269A Expired - Fee Related KR100547923B1 (ko) 1997-05-15 1998-05-15 생체내내성이증가된제제

Country Status (17)

Country Link
US (1) US6020315A (enExample)
EP (1) EP0879605B1 (enExample)
JP (1) JP4367798B2 (enExample)
KR (1) KR100547923B1 (enExample)
CN (1) CN1188134C (enExample)
AR (1) AR012694A1 (enExample)
AT (1) ATE333899T1 (enExample)
AU (1) AU740694B2 (enExample)
BR (1) BR9801632A (enExample)
CA (1) CA2237450A1 (enExample)
CZ (1) CZ149398A3 (enExample)
DE (2) DE19720312A1 (enExample)
HU (1) HUP9801087A3 (enExample)
ID (1) ID20283A (enExample)
PL (1) PL193478B1 (enExample)
RU (1) RU2234322C2 (enExample)
TR (1) TR199800848A3 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701042B2 (en) * 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
SK283803B6 (sk) * 1997-08-26 2004-02-03 Aventis Pharmaceuticals Inc. Farmaceutický prostriedok vo forme dvojvrstvovej tabletky na kombinovanie piperidinoalkanolu s dekongestantom
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002214649A1 (en) * 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
EP1938821B1 (en) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
WO2003015759A2 (en) * 2001-08-14 2003-02-27 Valderm Aps Treatment of hyperproliferative conditions of body surfaces
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
ES2389532T3 (es) 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026453A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of inflammatory disorders with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
JPH06293665A (ja) * 1992-10-27 1994-10-21 Behringwerke Ag プロドラッグ、その製造および医薬としての使用
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
JPH06293665A (ja) * 1992-10-27 1994-10-21 Behringwerke Ag プロドラッグ、その製造および医薬としての使用
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochem Pharmacol. 1996 Aug 9;52(3):455-63., p.457의 Fig.1 *
Biochem. Pharmacology, vol 52, pp. 455-463(1996) *

Also Published As

Publication number Publication date
AU6600598A (en) 1998-11-19
EP0879605A3 (de) 1998-12-02
JPH1129497A (ja) 1999-02-02
PL193478B1 (pl) 2007-02-28
TR199800848A2 (xx) 1998-12-21
KR19980087239A (ko) 1998-12-05
DE59813653D1 (de) 2006-09-07
ID20283A (id) 1998-11-19
HUP9801087A2 (hu) 1998-12-28
TR199800848A3 (tr) 1998-12-21
HUP9801087A3 (en) 1999-05-28
CA2237450A1 (en) 1998-11-15
JP4367798B2 (ja) 2009-11-18
CZ149398A3 (cs) 1998-12-16
ATE333899T1 (de) 2006-08-15
CN1188134C (zh) 2005-02-09
AU740694B2 (en) 2001-11-15
CN1199613A (zh) 1998-11-25
US6020315A (en) 2000-02-01
DE19720312A1 (de) 1998-11-19
EP0879605B1 (de) 2006-07-26
EP0879605A2 (de) 1998-11-25
BR9801632A (pt) 1999-06-29
AR012694A1 (es) 2000-11-08
HU9801087D0 (en) 1998-07-28
PL326336A1 (en) 1998-11-23
RU2234322C2 (ru) 2004-08-20

Similar Documents

Publication Publication Date Title
KR100547923B1 (ko) 생체내내성이증가된제제
KR100297862B1 (ko) 선구약물 및 이의 제조방법
AU2001273670B2 (en) Pyrido(2,3-d)pyrimidine and pyrimido(4,5-d)pyrimidine nucleosides
EP0795334B1 (de) Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
Henin et al. Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study and antiviral activity
US6420377B1 (en) Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US20130012466A1 (en) Colchicine neoglycosides and methods for their synthesis and use
JP2012522842A (ja) シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
Parker et al. N-Trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies
SI20976A (sl) Sestavki in postopki za L-nukleozide, L-nukleotide in njihove analoge
US8278436B2 (en) Glycosylated warfarin analogs and uses thereof
US8552176B2 (en) Glycosylated chlorambucil analogs and uses thereof
MXPA98003847A (en) Prepared with in vivo increment compatibility
Arcamone et al. Doxorubicin and related compounds. II. Structure-activity considerations
WO2025177173A1 (en) Polymers useful for conjugating to antibodies and therapeutic uses thereof
WO2005111056A1 (en) New esters of adenosine nucleosides and carboxylic acid
Shen Studies on Glycopharmaceuticals, HDACI and No-donors
Cai Synthesis of novel nitric oxide donors and prodrugs of 5-fluorouracil

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090125

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090125

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000